Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia

Elena Arriazu, Raffaella Pippa, María D. Odero (Lead / Corresponding author)

Research output: Contribution to journalArticle

8 Citations (Scopus)
57 Downloads (Pure)

Abstract

Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Despite progressive advances in our understanding of the molecular biology of this disease, the outcome for most patients is poor. It is, therefore, necessary to develop more effective treatment strategies. Genetic aberrations affecting kinases have been widely studied in AML; however, the role of phosphatases remains underexplored. Inactivation of the tumor-suppressor protein phosphatase 2A (PP2A) is frequent in AML patients, making it a promising target for therapy. There are several PP2A inactivating mechanisms reported in this disease. Deregulation or specific post-translational modifications of PP2A subunits have been identified as a cause of PP2A malfunction, which lead to deregulation of proliferation or apoptosis pathways, depending on the subunit affected. Likewise, overexpression of either SET or cancerous inhibitor of protein phosphatase 2A, endogenous inhibitors of PP2A, is a recurrent event in AML that impairs PP2A activity, contributing to leukemogenesis progression. Interestingly, the anticancer activity of several PP2A-activating drugs (PADs) depends on interaction/sequestration of SET. Preclinical studies show that pharmacological restoration of PP2A activity by PADs effectively antagonizes leukemogenesis, and that these drugs have synergistic cytotoxic effects with conventional chemotherapy and kinase inhibitors, opening new possibilities for personalized treatment in AML patients, especially in cases with SET-dependent inactivation of PP2A. Here, we review the role of PP2A as a druggable tumor suppressor in AML.

Original languageEnglish
Article number78
JournalFrontiers in Oncology
Volume6
Issue numberAPR
DOIs
Publication statusPublished - 6 Apr 2016

Fingerprint

Protein Phosphatase 2
Acute Myeloid Leukemia
Therapeutics
Core Binding Factor alpha Subunits
Phosphotransferases
Pharmaceutical Preparations
Tumor Suppressor Proteins
Post Translational Protein Processing
Hematopoietic Stem Cells
Phosphoric Monoester Hydrolases
Epigenomics
Molecular Biology
Pharmacology

Keywords

  • AML
  • FTY720
  • OP449
  • PP2A
  • SET

Cite this

Arriazu, Elena ; Pippa, Raffaella ; Odero, María D. / Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia. In: Frontiers in Oncology. 2016 ; Vol. 6, No. APR.
@article{4a9d1865fe6648aba113d5f99240ddac,
title = "Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia",
abstract = "Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Despite progressive advances in our understanding of the molecular biology of this disease, the outcome for most patients is poor. It is, therefore, necessary to develop more effective treatment strategies. Genetic aberrations affecting kinases have been widely studied in AML; however, the role of phosphatases remains underexplored. Inactivation of the tumor-suppressor protein phosphatase 2A (PP2A) is frequent in AML patients, making it a promising target for therapy. There are several PP2A inactivating mechanisms reported in this disease. Deregulation or specific post-translational modifications of PP2A subunits have been identified as a cause of PP2A malfunction, which lead to deregulation of proliferation or apoptosis pathways, depending on the subunit affected. Likewise, overexpression of either SET or cancerous inhibitor of protein phosphatase 2A, endogenous inhibitors of PP2A, is a recurrent event in AML that impairs PP2A activity, contributing to leukemogenesis progression. Interestingly, the anticancer activity of several PP2A-activating drugs (PADs) depends on interaction/sequestration of SET. Preclinical studies show that pharmacological restoration of PP2A activity by PADs effectively antagonizes leukemogenesis, and that these drugs have synergistic cytotoxic effects with conventional chemotherapy and kinase inhibitors, opening new possibilities for personalized treatment in AML patients, especially in cases with SET-dependent inactivation of PP2A. Here, we review the role of PP2A as a druggable tumor suppressor in AML.",
keywords = "AML, FTY720, OP449, PP2A, SET",
author = "Elena Arriazu and Raffaella Pippa and Odero, {Mar{\'i}a D.}",
year = "2016",
month = "4",
day = "6",
doi = "10.3389/fonc.2016.00078",
language = "English",
volume = "6",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media",
number = "APR",

}

Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia. / Arriazu, Elena; Pippa, Raffaella; Odero, María D. (Lead / Corresponding author).

In: Frontiers in Oncology, Vol. 6, No. APR, 78, 06.04.2016.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Protein phosphatase 2A as a therapeutic target in acute myeloid leukemia

AU - Arriazu, Elena

AU - Pippa, Raffaella

AU - Odero, María D.

PY - 2016/4/6

Y1 - 2016/4/6

N2 - Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Despite progressive advances in our understanding of the molecular biology of this disease, the outcome for most patients is poor. It is, therefore, necessary to develop more effective treatment strategies. Genetic aberrations affecting kinases have been widely studied in AML; however, the role of phosphatases remains underexplored. Inactivation of the tumor-suppressor protein phosphatase 2A (PP2A) is frequent in AML patients, making it a promising target for therapy. There are several PP2A inactivating mechanisms reported in this disease. Deregulation or specific post-translational modifications of PP2A subunits have been identified as a cause of PP2A malfunction, which lead to deregulation of proliferation or apoptosis pathways, depending on the subunit affected. Likewise, overexpression of either SET or cancerous inhibitor of protein phosphatase 2A, endogenous inhibitors of PP2A, is a recurrent event in AML that impairs PP2A activity, contributing to leukemogenesis progression. Interestingly, the anticancer activity of several PP2A-activating drugs (PADs) depends on interaction/sequestration of SET. Preclinical studies show that pharmacological restoration of PP2A activity by PADs effectively antagonizes leukemogenesis, and that these drugs have synergistic cytotoxic effects with conventional chemotherapy and kinase inhibitors, opening new possibilities for personalized treatment in AML patients, especially in cases with SET-dependent inactivation of PP2A. Here, we review the role of PP2A as a druggable tumor suppressor in AML.

AB - Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Despite progressive advances in our understanding of the molecular biology of this disease, the outcome for most patients is poor. It is, therefore, necessary to develop more effective treatment strategies. Genetic aberrations affecting kinases have been widely studied in AML; however, the role of phosphatases remains underexplored. Inactivation of the tumor-suppressor protein phosphatase 2A (PP2A) is frequent in AML patients, making it a promising target for therapy. There are several PP2A inactivating mechanisms reported in this disease. Deregulation or specific post-translational modifications of PP2A subunits have been identified as a cause of PP2A malfunction, which lead to deregulation of proliferation or apoptosis pathways, depending on the subunit affected. Likewise, overexpression of either SET or cancerous inhibitor of protein phosphatase 2A, endogenous inhibitors of PP2A, is a recurrent event in AML that impairs PP2A activity, contributing to leukemogenesis progression. Interestingly, the anticancer activity of several PP2A-activating drugs (PADs) depends on interaction/sequestration of SET. Preclinical studies show that pharmacological restoration of PP2A activity by PADs effectively antagonizes leukemogenesis, and that these drugs have synergistic cytotoxic effects with conventional chemotherapy and kinase inhibitors, opening new possibilities for personalized treatment in AML patients, especially in cases with SET-dependent inactivation of PP2A. Here, we review the role of PP2A as a druggable tumor suppressor in AML.

KW - AML

KW - FTY720

KW - OP449

KW - PP2A

KW - SET

UR - http://www.scopus.com/inward/record.url?scp=84973514607&partnerID=8YFLogxK

U2 - 10.3389/fonc.2016.00078

DO - 10.3389/fonc.2016.00078

M3 - Article

VL - 6

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - APR

M1 - 78

ER -